With the spread of the AIDS pandemic, opportunistic fungal pathogens like Cryptococcus neoformans are a growing cause of morbidity and mortality among immunocompromised populations worldwide. In part owing to a common eukaryotic ancestry that results in shared physiology between fungal and human cells, these fungal infections are difficult to treat. The limited antifungal agents currently available therefore tend to target the few key differences between the two systems to avoid inadvertently harming the host. To address the current paucity of antifungal therapeutic agents, further research into fungal-specific drug targets is required. Adenylosuccinate synthetase (AdSS) is a crucial enzyme in the ATP biosynthetic pathway, catalyzing the magnesium-and GTP-dependant formation of adenylosuccinate from inosine monophosphate and aspartate.Over the course of my project I have investigated the potential of this enzyme as an antifungal drug target. By deleting the AdSS-encoding ADE12 gene from the C. neoformans genome, I found that loss of AdSS function results in adenine auxotrophy in C. neoformans, as well as complete loss of virulence in a murine infection model. In contrast, deleting the APH1 gene, encoding the adenine salvage enzyme adenine phosphoribosyltransferase, had no deleterious effects on cell growth or virulence in the murine model. I expressed and purified Cryptococcal AdSS from Escherichia coli and optimised conditions to generate high-quality AdSS protein crystals. These were used to complete X-ray diffractions studies, allowing me to determine the crystal structure of the enzyme. The structure of the enzyme's unbound form was solved first, and then used to solve the structure of the enzyme ligated with IMP and GDP. These are the first examples of an AdSS crystal structure from a fungal species. Together with enzyme kinetic studies, this structural information allowed me to compare the fungal enzyme with the human ortholog. This revealed species-specific differences that are potentially exploitable via rational drug design. These results validate AdSS as a promising antifungal drug target and lay a foundation for future in silico and in vitro screens for novel antifungal compounds.3